Literature DB >> 28648755

High Expression of Long Noncoding RNA MALAT1 Indicates a Poor Prognosis and Promotes Clinical Progression and Metastasis in Bladder Cancer.

Chao Li1, Yu Cui1, Long-Fei Liu1, Wen-Biao Ren1, Qia-Qia Li1, Xu Zhou1, Yang-Le Li1, Yang Li1, Xiang-Yang Bai2, Xiong-Bing Zu3.   

Abstract

BACKGROUND: Recent studies have demonstrated that the expression of long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) promotes cancer cell proliferation, invasion, and metastasis in many tumor types, but the association between bladder cancer and MALAT1 remains unknown. MATERIALS: The expression of MALAT1 was tested by in situ hybridization (ISH) in 120 bladder cancer specimens. The association between MALAT1 expression and clinicopathological features and prognosis of the patients with bladder cancer was analyzed. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to verify the relationship between the expression of MALAT1 and progression and metastasis of bladder cancer.
RESULTS: ISH showed that high MALAT1 expression was associated with advanced histological grade, high tumor stage, and positive lymph nodes. Kaplan-Meier survival analysis and Cox regression analysis indicated that high tumor stage, positive lymph nodes, and high MALAT1 expression were independent prognostic indicators for overall survival (OS) of patients with bladder cancer. qRT-PCR showed that the expression of MALAT1 in bladder cancer tissues was 2.85 times higher than those measured in adjacent normal tissues (P < .001). The expression of MALAT1 was 2.673 ± 0.254 in non-muscle-invasive bladder cancer and 2.987 ± 0.381 in muscle-invasive bladder cancer (P = .018). In bladder cancer specimens with positive lymph nodes, MALAT1 expression was 3.167 ± 0.297 versus 2.896 ± 0.329 in bladder cancer specimens with negative lymph nodes (P = .020).
CONCLUSION: High MALAT1 expression could serve as an independent prognostic factor for OS of patients with bladder cancer and could be considered as a potential therapeutic target of bladder cancer.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Diagnosis; Lymph node metastasis; Survival analysis; Tumor biology

Mesh:

Substances:

Year:  2017        PMID: 28648755     DOI: 10.1016/j.clgc.2017.05.001

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  32 in total

Review 1.  Long non-coding RNA expression in bladder cancer.

Authors:  Mohammad Taheri; Mir Davood Omrani; Soudeh Ghafouri-Fard
Journal:  Biophys Rev       Date:  2017-12-08

2.  miR-188-5p and Host MALAT1 Regulate RBE Cell Migration, Invasion, and Apoptosis via Up-regulating PSMD10 in Cholangiocarcinoma.

Authors:  Zhaoqiang Yin; Jianlong Wang; Tao Li; Lifeng Ma; Jiansheng Kang; Guochao Liu
Journal:  Appl Biochem Biotechnol       Date:  2022-09-19       Impact factor: 3.094

3.  Down-regulated LncR-MALAT1 suppressed cell proliferation and migration by inactivating autophagy in bladder cancer.

Authors:  Jiude Qi; Yanfeng Chu; Guangyan Zhang; Hongjun Li; Dongdong Yang; Qi Wang
Journal:  RSC Adv       Date:  2018-09-04       Impact factor: 4.036

4.  Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review.

Authors:  Guoming Su; Qili He; June Wang
Journal:  Front Physiol       Date:  2018-05-30       Impact factor: 4.566

5.  Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.

Authors:  Lutao Du; Weili Duan; Xiumei Jiang; Li Zhao; Juan Li; Rui Wang; Suzhen Yan; Yujiao Xie; Keqiang Yan; Qingliang Wang; Lili Wang; Yongmei Yang; Chuanxin Wang
Journal:  J Cell Mol Med       Date:  2018-03-08       Impact factor: 5.310

Review 6.  MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches.

Authors:  Nicola Amodio; Lavinia Raimondi; Giada Juli; Maria Angelica Stamato; Daniele Caracciolo; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  J Hematol Oncol       Date:  2018-05-08       Impact factor: 17.388

7.  Clinicopathological and prognostic significance of long noncoding RNA MALAT1 in human cancers: a review and meta-analysis.

Authors:  Juan Li; Zhigang Cui; Hang Li; Xiaoting Lv; Min Gao; Zitai Yang; Yanhong Bi; Ziwei Zhang; Shengli Wang; Baosen Zhou; Zhihua Yin
Journal:  Cancer Cell Int       Date:  2018-08-06       Impact factor: 5.722

8.  A comprehensive evaluation of differentially expressed mRNAs and lncRNAs in cystitis glandularis with gene ontology, KEGG pathway, and ceRNA network analysis.

Authors:  Chao Li; Jiao Hu; Peihua Liu; Qiaqia Li; Jinbo Chen; Yu Cui; Xu Zhou; Bichen Xue; Xin Zhang; Xin Gao; Xiongbing Zu
Journal:  Transl Androl Urol       Date:  2020-04

9.  MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer.

Authors:  Huaqi Wang; Li Wang; Guojun Zhang; Chunya Lu; Heying Chu; Rui Yang; Guoqiang Zhao
Journal:  Oncotarget       Date:  2017-12-14

10.  MALAT1 affects ovarian cancer cell behavior and patient survival.

Authors:  Qunbo Lin; Wencai Guan; Weimin Ren; Lingyun Zhang; Jinguo Zhang; Guoxiong Xu
Journal:  Oncol Rep       Date:  2018-04-19       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.